

## Combating Rising Antimicrobial Resistance: Advancing Public Health Preparedness, Antibiotics, & Innovation

Duke-Margolis Center for Health Policy

Webinar Agenda | May 12, 2021 | 11:00 am – 12:30 pm ET

**11:00 am**      **Welcome and Opening Remarks**

**Mark McClellan**, Director, Duke-Margolis Center for Health Policy

**Scott Gottlieb**, Resident Fellow, American Enterprise Institute

**11:10 am**      **A Conversation With Senator Michael Bennet: Investing in Preparedness to Sustain Innovation and Protect Public Health**

**Mark McClellan** moderates a conversation with **Senator Michael Bennet** that will explore increasing attention toward AMR and why U.S. investments in public health preparedness and innovation are both timely and critically important.

**11:25 am**      **Session 2: Global Policy Leadership and Proposals to Combat AMR**

This session will highlight how the U.S. can lead policy approaches to combat AMR through existing legislative proposals and opportunities to coordinate domestic actions with existing international efforts. Panelists will explore how to:

- Maintain political momentum toward substantial domestic pull-incentives for novel antibiotics, including the proposed PASTEUR and SUPERBUGS Acts;
- Leverage G7 and G20 leadership opportunities;
- Coordinate domestic and international actions to combat AMR; and
- Engage policymakers, legislators, and private-sector partners to advance immediate next steps.

*Panel Discussion*

- **Candace Dematteis**, Partnership to Fight Infectious Disease (PFID)
- **Lynn Filpi**, Office of Global Affairs, Office of the Secretary, HHS
- **Silas Holland**, AMR Action Fund
- **Kevin Outtersen**, CARB-X & Boston University

**11:55 am**      **Session 3: Innovations to Combat AMR and Emerging Infectious Diseases**

This session will focus on how to prepare for future pandemics and public health threats, as well as lessons learned from the coronavirus pandemic that might be applied to prevent or respond to rising AMR and threatening emerging infectious diseases. Panelists will explore how to:

- Prepare U.S. government agencies, drug and vaccine developers, manufacturers, and supply chain partners for future threats;

- Support flexible and affordable U.S. manufacturing and supply chain infrastructure;
- Support enhanced domestic and global threat surveillance; and
- Maintain ongoing support for rapid diagnostic capacity and innovation.

*Panel Discussion*

- **Allan Coukell**, CivicaRx
- **Michael Craig**, Centers for Disease Control & Prevention
- **John H. Rex**, F2G Ltd. & Advent Life Sciences

**12:25 pm**      **Closing Remarks**

**Mark McClellan**, Director, Duke-Margolis Center for Health Policy

**12:30 pm**      **Adjournment**